Evotec SE (EVO) Cash from Operations Growth (1y) (2010 - 2026)
Evotec SE (EVO) Cash from Operations Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 61.90% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -22.14% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 8.20% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 0.46% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -27.49% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 125.00% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 425.00% |
| 10 | Evotec SE | 351.60 Mn | 351.08 Mn | - | 86.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 86.30% |
| Dec 31, 2025 | -154.28% |
| Sep 30, 2025 | -268.82% |
| Jun 30, 2025 | 155.36% |
| Mar 31, 2025 | 36.07% |
| Dec 31, 2024 | -50.16% |
| Sep 30, 2024 | 94.72% |
| Jun 30, 2024 | -704.12% |
| Mar 31, 2024 | -7,889.36% |
| Dec 31, 2023 | -81.32% |
| Sep 30, 2023 | 699.60% |
| Jun 30, 2023 | -103.58% |
| Mar 31, 2023 | -99.06% |
| Dec 31, 2022 | 44.89% |
| Sep 30, 2022 | -116.34% |
| Jun 30, 2022 | 281.54% |
| Mar 31, 2022 | 2,407,103.00% |
| Jun 30, 2010 | -124.58% |
| Mar 31, 2010 | -130.52% |